Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience

BACKGROUND: Lenvatinib treatment of 24 mg/day for radioiodine-refractory differentiated thyroid carcinoma (RRDTC) patients was almost intolerable, with high rates of dose reduction, interruption and discontinuation. Balancing treatment safety with disease risks remains challenging, and the appropria...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, He-Jiun, Chang, Yen-Hsiang, Chen, Yen-Hao, Wu, Che-Wei, Wang, Pei-Wen, Hsiao, Pi-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449554/
https://www.ncbi.nlm.nih.gov/pubmed/34548818
http://dx.doi.org/10.2147/CMAR.S326255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449554/
https://www.ncbi.nlm.nih.gov/pubmed/34548818
http://dx.doi.org/10.2147/CMAR.S326255

Ejemplares similares